Therefore, awaiting publication of randomized controlled trials which are in the pipeline, a robust meta-analysis was conducted with a large sample size to illustrate the effects of GLP1-RA in patients with T2D and NAFLD, exclusively, to explore the impact of an additional medication to treat this twin threat. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.